COVID-19 CVD Registry
To better understand the COVID-19 pandemic, the American Heart Association has developed a new registry for hospitals and health systems caring for COVID-19 patients.
AUDIOCAST SERIES - Quality Improvement in the Time of COVID-19 NOW AVAILABLE
As physicians, scientists and researchers worldwide struggle to understand the novel coronavirus (COVID-19) pandemic, the American Heart Association (AHA) is developing a novel registry to aggregate data and aid research on the disease, treatment protocols and risk factors tied to adverse cardiovascular outcomes.
”Having sufficient data is the first step to understanding the impact of COVID-19 on cardiovascular health,“ said John Warner, M.D., FAHA, chair of the quality oversight committee and past volunteer president of the American Heart Association and executive vice president for Health System Affairs at the University of Texas Southwestern Health System in Dallas, Texas. “As a trusted resource for data and research, with an entry point in more than 2,400 U.S. hospitals, the American Heart Association is uniquely positioned to gather data quickly and accurately.”
"Having sufficient data is the first step to understanding the impact of COVID-19 on cardiovascular health"
-John Warner, M.D., FAHA
Several studies have reported COVID-19 patients presenting with or developing heart failure, cardiogenic shock, stroke and lethal arrhythmias secondary to the disease. However, these studies have consistently been limited by the lack of a structured collection of data raising concerns about indication bias for most laboratory testing. Further, several of these studies are single-center descriptive assessments, limiting their generalizability.
The AHA has created a quality improvement registry to better understand the clinical treatment patterns and variations, including the collection of biomarkers, and cardiovascular outcomes in hospitalized COVID-19 patients across the nation. The registry will focus on real-time data from acute care hospitals to better help clinicians and researchers understand and provide feedback to healthcare organizations on how to best treat COVID-19 patients.
The AHA’s COVID-19 CVD Registry powered by Get With The Guidelines® (GWTG) builds on 20 years of successful hospital quality improvement efforts. The no-cost registry will help inform the larger medical community and the aggregated, deidentified data set will be available to researchers through the Association’s Institute for Precision Cardiovascular Medicine in coming months.
Thank You to Our Participating Hospitals!
The American Heart Association recognizes and thanks these hospitals for leading the way toward better health.
Data collection and feedback reporting are performed using the American Heart Association's IQVIA Registry Platform, an online interactive system provided by IQVIA. Enhancements have been made since the release of the COVID-19 CVD Registry to allow for bulk upload of data to reduce abstraction burden.
Benefits of Participation
In addition to being specifically designed to track all hospitalized COVID-19 patients to get real-time feedback from across the nation, the registry will include the following features:
- Access to national and regional benchmarks
- Ability to use key learnings and data for future pandemic preparedness
- Leverage the registry for powerful rapid research
- Future iterations will include enhanced measures and reports
How to Enroll
In response, the AHA is creating the multicenter registry to collect biomarkers, clinical data and cardiovascular outcomes in COVID-19 patients. The registry will focus on granular data collection from centers that routinely test biomarkers in COVID-19 patients.
Additional resources and guidance for health care professionals on COVID-19 can be found here.
Support from the American Heart Association